Tricuspid atresia medical therapy: Difference between revisions
Jump to navigation
Jump to search
(/* ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease (DO NOT EDIT){{cite journal| author=Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA et al.| title=ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines for the management of adults with conge...) |
|||
| (9 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Template:Tricuspid atresia}} | {{Template:Tricuspid atresia}} | ||
{{CMG}}; '''Associate Editor-In-Chief:''' [[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu] [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com]; '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [mailto:kfeeney@elon.edu] | {{CMG}}; '''Associate Editor-In-Chief:''' {{Sara.Zand}}[[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu] [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com]; '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [mailto:kfeeney@elon.edu] | ||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
==Overview== | |||
The mainstay of therapy for the cyanotic neonate with severe [[ pulmonary stenosis]] and small-sized [[VSD]] is using [[ prostaglandin E1]] (PGE1) for keeping patency of [[ductus arteriosis]]. The mainstay of therapy for [[heart failure]] symptoms is using [[diuretic]] for reduction of [[congestion]] and then starting [[ ACEI]]. | |||
== Medical Therapy == | |||
*The mainstay of therapy for the cyanotic neonate with severe [[ pulmonary stenosis]] and small-sized [[VSD]] is using [[ prostaglandin E1]] (PGE1) for keeping patency of [[ductus arteriosis]].<ref name="AkkinapallyHundalani2018">{{cite journal|last1=Akkinapally|first1=Smita|last2=Hundalani|first2=Shilpa G|last3=Kulkarni|first3=Madhulika|last4=Fernandes|first4=Caraciolo J|last5=Cabrera|first5=Antonio G|last6=Shivanna|first6=Binoy|last7=Pammi|first7=Mohan|title=Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions|journal=Cochrane Database of Systematic Reviews|year=2018|issn=14651858|doi=10.1002/14651858.CD011417.pub2}}</ref> | |||
*The mainstay of therapy for [[heart failure]] symptoms is using [[diuretic]] for reduction of [[congestion]] and then starting [[ ACEI]]. | |||
==References== | ==References== | ||
Latest revision as of 19:30, 8 November 2020
|
Tricuspid atresia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenarios |
|
Case Studies |
|
Tricuspid atresia medical therapy On the Web |
|
American Roentgen Ray Society Images of Tricuspid atresia medical therapy |
|
Risk calculators and risk factors for Tricuspid atresia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Sara Zand, M.D.[2]Keri Shafer, M.D. [3] Priyamvada Singh, MBBS [4]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [5]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
The mainstay of therapy for the cyanotic neonate with severe pulmonary stenosis and small-sized VSD is using prostaglandin E1 (PGE1) for keeping patency of ductus arteriosis. The mainstay of therapy for heart failure symptoms is using diuretic for reduction of congestion and then starting ACEI.
Medical Therapy
- The mainstay of therapy for the cyanotic neonate with severe pulmonary stenosis and small-sized VSD is using prostaglandin E1 (PGE1) for keeping patency of ductus arteriosis.[1]
- The mainstay of therapy for heart failure symptoms is using diuretic for reduction of congestion and then starting ACEI.
References
- ↑ Akkinapally, Smita; Hundalani, Shilpa G; Kulkarni, Madhulika; Fernandes, Caraciolo J; Cabrera, Antonio G; Shivanna, Binoy; Pammi, Mohan (2018). "Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD011417.pub2. ISSN 1465-1858.